News | January 18, 2026
JB Pharma Q3 FY26 PAT up by 22% to Rs. 198 Cr
The company recorded revenue of Rs. 1,065 crore in the third quarter of FY26
The company recorded revenue of Rs. 1,065 crore in the third quarter of FY26
Favorable outcome would contribute to significantly containing the Roundup litigation as the company continues its multi-pronged strategy
The BEAR Implant is the first sports medicine device to carry a label claim related to lowering PTOA risk
GCCL aims to leverage the partnership to expand strategic relationships with global CROs
The launch of PatroLab is a pivotal milestone, marking a paradigm shift in biologics development and manufacturing
ATEC secures exclusive U.S. commercial rights to Theradaptive’s OsteoAdapt osteoinductive bone graft, currently in clinical trials for spinal and dental applications
The trial aims to assess the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of the combination therapy
Approval marks Venus Remedies’ first anti-infective marketing authorization in Indonesia and enables the country’s first generic entry for this critical antibiotic combination
UNLOXCYT is an evolution in checkpoint inhibition and is now available for the treatment of adults in the U.S. with mCSCC or laCSCC who are not candidates for curative surgery or curative radiation
The partnership aims to fuse Avantium’s breakthrough materials with Packamama’s expertise in low-emission, innovative wine bottles
Subscribe To Our Newsletter & Stay Updated
